Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal cancer, which was successfully translated into a non-invasive liquid biopsy assay for predicting responses to anti-EGFR therapy. The gene discussed is KRAS; the disease is metastatic colorectal cancer.